((1S,9S)-11-{[4-(1,3-BENZODIOXOL-5-YLAMINO)-8-METHYL-2-QUINAZOLINYL]METHYL} -7,11-DIAZATRICYCLO[7.3.1.0~2,7~]TRIDECA-2,4-DIEN-6-ONE) AS A STABILIZER OF CRYS FOR THE TREATMENT OF CIRCADIAN RHYTHM ASSOCIATED DISEASES AND DISORDERS

((1S,9S)-11-{[4-(1,3-BENZODIOXOL-5-YLAMINO)-8-METHYL-2-QUINAZOLINYL]METHYL} -7,11-DIAZATRICYCLO[7.3.1.0~2,7~]TRIDECA-2,4-DIEN-6-ONE) AS A STABILIZER OF CRYS FOR THE TREATMENT OF CIRCADIAN RHYTHM ASSOCIATED DISEASES AND DISORDERS

The present invention relates to ((1S,9S)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl}-7,11-diazatricyclo[7.3.1.0~2,7~] trideca-2,4-dien-6-one) compound and related derivatives. The compound of the invention is a CRY1/2-binding small molecule and also a stabilizer of CRY1 and C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: GÜL, Şeref, GÜZEL, Mustafa, ŞAVLUĞ İPEK, Özgecan, AYDIN, Cihan, TÜRKAY, Metin, KAVAKLI, İbrahim Halil, ERGÜN, Çağla
Format: Patent
Sprache:eng ; fre
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to ((1S,9S)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl}-7,11-diazatricyclo[7.3.1.0~2,7~] trideca-2,4-dien-6-one) compound and related derivatives. The compound of the invention is a CRY1/2-binding small molecule and also a stabilizer of CRY1 and CRY2 proteins, and is therefore useful, as pharmaceutical agent, especially in the treatment and/or prevention of disorders associated with the circadian rhythm, including CRY1-mediated diseases such as diabetes. La présente invention concerne un composé ((1S,9S)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-méthyl-2-quinazolinyl]méthyl}-7,11-diazatricyclo[7.3.1.0~2,7~] trideca-2,4-dièn-6-one) et des dérivés apparentés. Le composé de l'invention est une petite molécule de liaison de CRY1/2 et également un stabilisant de protéines CRY1 et CRY2, et est par conséquent utile, en tant qu'agent pharmaceutique, en particulier dans le traitement et/ou la prévention de troubles associés au rythme circadien, comprenant des maladies médiées par CRY1, telles que le diabète.